| Target Price | $26.01 |
| Price | $6.87 |
| Potential |
278.60%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Bicycle Therapeutics Plc 2026 .
The average Bicycle Therapeutics Plc target price is $26.01.
This is
278.60%
register free of charge
$46.20
572.49%
register free of charge
$10.10
47.02%
register free of charge
|
|
| A rating was issued by 20 analysts: 15 Analysts recommend Bicycle Therapeutics Plc to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Bicycle Therapeutics Plc stock has an average upside potential 2026 of
278.60%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 35.28 | 28.87 |
| 30.76% | 18.18% | |
| EBITDA Margin | -572.51% | -1,027.23% |
| 15.51% | 79.43% | |
| Net Margin | -479.11% | -1,024.43% |
| 28.45% | 113.82% |
17 Analysts have issued a sales forecast Bicycle Therapeutics Plc 2025 . The average Bicycle Therapeutics Plc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Bicycle Therapeutics Plc EBITDA forecast 2025. The average Bicycle Therapeutics Plc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Bicycle Therapeutics Plc Analysts have issued a net profit forecast 2025. The average Bicycle Therapeutics Plc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.90 | -4.27 |
| 42.91% | 47.24% | |
| P/E | negative | |
| EV/Sales | negative |
16 Analysts have issued a Bicycle Therapeutics Plc forecast for earnings per share. The average Bicycle Therapeutics Plc EPS is
This results in the following potential growth metrics and future valuations:
Bicycle Therapeutics Plc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Citizens |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jul 17 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | May 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Citizens:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jul 17 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
May 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


